Leprosy: When to raise suspicion

Nurse Practitioner

Volumn 38, Issue 2, 2013, Pages 10-14

  Luchtefeld, William ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; HUMAN; LEPROSY; MALE; NURSE PRACTITIONER; NURSING; NURSING DIAGNOSIS; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; UNITED STATES; WORLD HEALTH ORGANIZATION;

ADULT; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HUMANS; LEPROSY; MALE; NURSE PRACTITIONERS; NURSING DIAGNOSIS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 84876219947     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000425834.98059.ae     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;59(53):1-111.
2. World Health Organization, Weekly Epidemiological Record, 2 2011;36(86):389-400.
3. HRSA. Frequently asked questions about Hansen Disease. http://www.hrsa.gov/hansensdisease/pdfs/faq.pdf.
4. Job CK, Jayakumar J, Kearney M, Gillis T P. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg. 2008;78(3):518-521.
5. Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011;364(17):1626-1633.
6. Zhang FR, Huang W, Chen SM. Genomewide association study of leprosy. N Engl J Med. 2009;361(27):2609-2618.
7. Smith C, Richardus JH. Leprosy strategy is about control, not eradication. Lancet. 2008;371(9617):969-970.
8. Moet F, Pahan D, Schuring R, Oskam L, Richardus J. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infec Diseases 2006;193:346-353.
9. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255-273.
10. HRSA. Classification for treatment purposes. http://www.hrsa.gov/ hansensdisease/diagnosis/classification. html.
11. WHO. National policy guidelines for TB/HIV collaborative activities in Uganda. http://www.who.int/hiv/pub/guidelines/uganda.pdf.
12. Withington S. Leprosy. In: G Cook and Zumla A. Manson' s Tropical Diseases. 22nd Edition. Saunders. 2009: Chapter 58.
13. Chaurasia RN, Garg RK, Singh MK, Verma R, Shukla R. Nerve conduction studies in pauci-bacillary and multibacillary leprosy: a comparative evaluation. Indian J Lepr. 2011;83(1):15-22.
14. Martinez AN, Ribeiro-Alves M, Sarno EN, Moraes MO. Evaluation of qPCR-based Assays for Leprosy Diagnosis Directly in Clinical Specimens. PLoS Negl Trop Dis. 2011;5(10):e1354.
15. Lobato J, Costa MP, Reis Ede M, et al. Comparison of three immunological tests for leprosy diagnosis and detection of subclinical infection. Lepr Rev. 2011;82(4):389-401.
16. WHO. WHO recommended MDT regimens. http://www.who.int/lep/mdt/regimens/ en/.
17. HRSA. Recommended treatment regimens. http://www.hrsa.gov/hansensdisease/ diagnosis/recommendedtreatment.html.
18. Setia MS, Shinde SS, Jerajani HR, Boivin JF. Is there a role for rifampicin, ofl oxacin and mino-cycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. Trop Med Int Health. 2011;16(12):1541-1551.
19. Franco-Paredes C, Jacob JT, Stryjewska B, Yoder L. Two patients with leprosy and the sudden appearance of infl ammation in the skin and new sensory loss. PLos Negl Trop Dis. 2009:3(9):e425.
20. Batista MD, Porro AM, Maeda SM, et al. Leprosy reversal reaction as immune reconstitution infl ammatory syndrome in patients with AIDS. Clin Infect Dis. 2008:46(6):e56-e60.
21. Bussone G, Charlier C, Bille E, Caux F, Levy A, Viard J, Lecuit M, Lortholary Case report: unmasking leprosy: an unusual immune recon-stitution syndrome in a patient infected with human immnodeficiency virus. Am J Trop Med Hyg. 2010;83:13-14.
22. Britton WJ, Lockwood DNJ. Leprosy. Lancet. 2004;363:1209-1219.
23. Lockwood D & McAdam K. Leprosy. In Infectious Diseases. 3rd ed. by Gorbach SL, Bartlett JG, Bartlett NR et al. Philadelphia PA: Lippincott Williams and Wilkins; 2004.
24. Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008;79(4):372-386.
25. Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev. 2007;78(3):197-215.
26. Proposed changes to approved Thalomid package insert. www.accessdata.fda.gov/drugsatfda-docs/label/2006/021430lbl.pdf.
27. Kaimal S, Thappa DM. Relapse in Leprosy. Indian J Dermatol Venereol Leprol 2009;75:126-135.
28. Moet F, Pahan D, Oskam L, Richardus J. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008;336:761.
29. Rodrigues LC, Lockwood DNJ. Lancet Infect Dis. 2011;11(6):464-470.
30. Medline Plus. Side effects. http://www.nlm.nih. gov/medlineplus/druginfo/ meds/a682403. html#side-effects
31. WHO. Leprosy elimination: Novartis and the Novartis Foundation. http://www.who.int/lep/partners/novartis/en/index.html.
32. Duppre NC, Camacho IA, De Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R SOc Trop Med Hyg. 2008;102:631-638.